News & Updates
Filter by Specialty:
Maximal androgen blockade the prime prostate cancer treatment option in older patients
Among prostate cancer patients aged ≥75 years, maximal androgen blockage (MAB) appears to be the most common treatment option, reports a new South Korea study. Meanwhile, the combination of leuprolide and bicalutamide is the most common MAB regimen.
Maximal androgen blockade the prime prostate cancer treatment option in older patients
16 Sep 2022
First-line rucaparib boosts PFS in ovarian cancer regardless of HRD status
First-line rucaparib maintenance therapy extends progression-free survival (PFS) in patients with ovarian, fallopian tube, or primary peritoneal cancer, according to results of the phase III ATHENA-MONO trial presented at the ESMO Gynaecological Cancers Conference 2022.
First-line rucaparib boosts PFS in ovarian cancer regardless of HRD status
15 Sep 2022
Older age, itch, pain predict depression in atopic dermatitis
Depressive symptoms are common among adults with atopic dermatitis (AD) severity and may fluctuate over time, reveals a study. Persistent depression is significantly associated with older age, male sex, severe itch, and skin pain, among others.
Older age, itch, pain predict depression in atopic dermatitis
15 Sep 2022
Roflumilast shows treatment potential for seborrheic dermatitis
In the phase III STRATUM* trial, the investigational PDE4** inhibitor roflumilast improved multiple symptoms of moderate-to-severe seborrheic dermatitis (SD).
